XOMA Provides Corporate Update and Reports Financial Results for Third Quarter 2015

Go back to XOMA Provides Corporate Update and Reports Financial Results for Third Quarter 2015

XOMA (XOMA) Uses License Deals and Restructuring to Extend Runway to 2017; Piper Jaffray Remains Neutral

November 6, 2015 10:35 AM EST

Piper Jaffray reiterated a Neutral rating on XOMA, Ltd. (NASDAQ: XOMA), and raised the price target to $1.80 (from $1.50), following the company's 3Q earnings report. XOMA ended 3Q:15 with $32 million. The company subsequently received $37 million from Novartis for TGF-beta upfront and $5 million from Agenus for an... More

Agenus (AGEN) to Acquire XOMA's (XOMA) Biologics Manufacturing Facilities

November 5, 2015 4:11 PM EST

XOMA (NASDAQ: XOMA) announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (Nasdaq: AGEN). The transaction is expected to close in December 2015. In conjunction with the transaction, Agenus will offer employment to a select team of XOMA employees currently operating the facilities and may provide... More

XOMA (XOMA) Tops Q3 EPS by 16c

November 5, 2015 4:02 PM EST

XOMA (NASDAQ: XOMA) reported Q3 EPS of $0.00, $0.16 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.55 million.

For earnings history and earnings-related data on XOMA (XOMA) click here.

... More